Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...
Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed ...
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
Job creation bounced back in November after disruptions from storms and a major strike, reinforcing a picture of modest expansion over the past few months. Everybody Loves FRED: How Americans Fell ...
The ‘Chilling’ Fatal Shooting of a C.E.O. Has Business Leaders on Edge After Brian Thompson of UnitedHealthcare was killed in Manhattan, the phones at corporate security firms were “ringing ...